Floatz logo

Gilteritinib

Anaplastic Lymphoma Kinase (ALK) Positive

Astellas Pharma Global Development, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Anaplastic Lymphoma Kinase (ALK) Positive cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Mingzhi Zhang
Phase 4BB
Crizotinib
Mingzhi Zhang
Phase 4BB
Inno-206
Huiqiang Huang
Phase 2BB
DEXAMETHASONE
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB

View all 33 →

Same molecule, other indications

Gilteritinib is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →